Argo Biopharma
PrivateLast Round
IPO
Nov 6, 2025
Total Funding Raised
$110M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Argo Biopharma operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series A Extension round in November 2023.
Argo Biopharma is a biotechnology company that develops next-generation siRNA therapeutics for various diseases, including cardiovascular, viral, metabolic, and rare conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Argo Biopharma Comparables
Compare Argo Biopharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sirius Therapeutics, Inc. | 87% | |
| Rona Therapeutics | 87% | |
| ADARx Pharmaceuticals | 85% |
For institutional investors. Book with your work email.
Argo Biopharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Nov 6, 2025 | ||||
| Series A Extension | Nov 1, 2023 | ||||
| Series A | Mar 23, 2022 | ||||
| Angel | May 1, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Argo Biopharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Loyal Valley Capital | Series A |
| Huagai Capital | Series A Extension |
| GSR United Capital | Series A |
| CS Capital | Series A Extension |
| Tao Capital Partners | Series A |
| CPE | Series A |
| Apricot Capital | Angel |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 3, 2026
Open roles increased to 397, 1203% of headcount.
- Jul 20, 2026
Open roles increased to 367, 1112% of headcount.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 4, 2026
Argo Biopharma is set to present updated Phase II results from the BW-20805 siRNA therapeutic study for hereditary angioedema at Bradykinin Symposium 2026 in Berlin, Germany, in Sep '26.
For institutional investors. Book with your work email.
Argo Biopharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Argo Biopharma's valuation, stock price, and market status.
Is Argo Biopharma a public or private company?
Argo Biopharma is a private company.
What is the current stock price of Argo Biopharma?
Argo Biopharma is a private company, so its shares have no public market price. Caplight tracks Argo Biopharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Argo Biopharma worth (valuation)?
Valuation information for Argo Biopharma is not publicly available.
Can I buy Argo Biopharma stock?
Argo Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Argo Biopharma's last funding round?
Argo Biopharma's most recent funding round was IPO on November 6, 2025.
Who are the main investors in Argo Biopharma?
Key investors in Argo Biopharma include Loyal Valley Capital, CS Capital, Apricot Capital.
Will Argo Biopharma IPO soon?
No public IPO plans have been announced for Argo Biopharma.
How can I track Argo Biopharma secondary market activity?
Caplight tracks bids, offers, and trades in Argo Biopharma's shares on secondary markets.